ArticleSkin appendage disorders2025
Using Disease Symptomatology to Guide Treatment in Patients with Central Centrifugal Cicatricial Alopecia: Introduction of C-CAT Scoring Tool.
Article in Skin appendage disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07734870 (Tirzepatide for Treatment of CCCA), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tirzepatide for Treatment of CCCA
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Central centrifugal cicatricial alopecia (CCCA) is a progressive scarring alopecia. No disease activity scale exists, making assessment of therapeutic intervention difficult. This study introduces the CCCA Clinical Assessment Tool (C-CAT), a novel scale that quantifies symptom severity to facilitate tailored treatment and track disease progression. Methods: A retrospective review of patients with CCCA was assessed on degree of pruritus, erythema, pain, disease progression, and scalp resistance, each scored from 0 to 2, over the course of a minimum of 6 months of therapy. Results: Eighty-two patients were included. The average initial C-CAT score was 3.4, consistent with mild to moderate disease activity. After 6 months of treatment, 88% of patients had improvement in score, with 48% of all patients achieving remission. Intralesional kenalog injections and topical clobetasol were the most commonly used therapies. Patients required an average of 3.6 different treatments to achieve therapeutic response. Conclusion: The C-CAT provides a structured, quantitative method to assess CCCA severity, which facilitates tracking of disease improvement for the majority of patients with targeted therapy. While the subjective nature of some C-CAT components may lead to inter-rater variability, this tool promotes personalized, symptom-based treatment and supports clinicians and patients in understanding this complex condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.